Partnership covers combinatorial therapies in cancer, related in silico models, and theranostics.
Life Biosystems and The University of Texas M. D. Anderson Cancer Center have entered into a broad 10-year research collaboration. The organizations signed a separate agreement, where in Life Biosystems will provide IT consulting to M. D. Anderson.
Under the research alliance, Life Biosystems will receive exclusive rights to commercialize intellectual property discovered from certain joint research projects.
The key areas of study will includes the rational prediction of combinatorial therapies to address the high nonresponder rates associated with all cancer therapies, the search for patient-validated targets and theranostics, the analysis of drug mode of action, and the identification of alternative uses and contraindications of drugs. The parties will also work together to develop in silico models to evaluate combinatorial therapy treatments for cancer patients.
Under the service deal, Life Biosystems will work closely with M. D. Anderson’s executive management team to help design, plan, and organize the replacement of the existing clinical trial protocol data management system with an updated comprehensive protocol management solution.
